On the risk of delisting of ordinary shares of Lexaria Bioscience Corp. (LEXX)

The International Trading System Limited (hereinafter — ITS) informs on the information concerning delisting risk of ordinary shares of Lexaria Bioscience Corp. (ISIN US52886N4060, Shares) from The Nasdaq Stock Market LLC (Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On April 4, 2025, Lexaria Bioscience Corp. (the Company) submitted Quarterly report on Form 10-Q for the quarterly period ended February 28, 2025 to The United States Securities and Exchange Commission. According to the report, the Company has incurred history of significant net losses, insufficient projected cash flows to meet financial obligations over the next twelve months, and uncertainty regarding the availability of future financing or strategic partnerships. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Previously, similar statements were made in the Company’s Quarterly reports on Form 10-Q for the quarterly period ended November 30, 2024.

Information regarding possible actions to be taken by ITS

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.